Organon & Co (OGN)
21.36
-0.60
(-2.76%)
USD |
NYSE |
May 23, 16:00
21.36
0.00 (0.00%)
After-Hours: 16:15
Organon Cash from Operations (TTM): 761.00M for March 31, 2024
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 761.00M |
| December 31, 2023 | 799.00M |
| September 30, 2023 | 669.00M |
| June 30, 2023 | 725.00M |
| March 31, 2023 | 849.00M |
| December 31, 2022 | 858.00M |
| September 30, 2022 | 638.00M |
| Date | Value |
|---|---|
| June 30, 2022 | 689.00M |
| March 31, 2022 | 1.077B |
| December 31, 2021 | 2.458B |
| September 30, 2021 | 2.841B |
| June 30, 2021 | 2.761B |
| March 31, 2021 | 3.025B |
| December 31, 2020 | 2.187B |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
638.00M
Minimum
Sep 2022
3.025B
Maximum
Mar 2021
1.453B
Average
853.50M
Median
Cash from Operations (TTM) Benchmarks
| Amgen Inc | 8.096B |
| Pfizer Inc | 8.578B |
| Pacira BioSciences Inc | 184.62M |
| Amphastar Pharmaceuticals Inc | 198.41M |
| Moderna Inc | -2.882B |